Enanta's virology pipeline includes the leading portfolio in development for RSV treatment, consisting of zelicapavir and EDP-323, both of which received Fast Track designation from the FDA. The company is building a leading immunology portfolio focused on type 2 immune driven diseases through KIT, STAT6 and MRGPRX2 inhibitors, with strong cash position and runway into fiscal 2029.
Cyborg Score Rationale
The company has $241.9M in cash with runway into fiscal 2029 and receives royalties from AbbVie's hepatitis C drug. Multiple near-term clinical catalysts in 2026 including IND filings and Phase 3 enabling activities for RSV programs position Enanta well, though clinical execution risks remain inherent to biotech stage.
Top Insights
Advancing discussions with FDA to align on adult Phase 3 study design for zelicapavir (RSV N-protein inhibitor) following positive Phase 2b results
EDP-323 (RSV L-protein inhibitor) demonstrated 87% viral load AUC reduction and strong post-exposure prophylaxis effect (0% infections vs 26% placebo) in human viral challenge
EPS-3903 (STAT6 inhibitor for atopic dermatitis) demonstrates preclinical efficacy comparable to dupilumab in disease models with favorable ADME properties
Three-year average net burn rate of 4.1% through fiscal 2025 indicates efficient capital deployment
Named Competitors
Dupilumab — Biologic for atopic dermatitis and allergic diseases; oral STAT6 inhibitors aim to offer convenient alternative
RSV antivirals (multiple programs) — Competing small molecule and biologic RSV treatments in clinical development
Recent Developments
(February 2026) Presented preclinical data for EDP-978 KIT inhibitor at AAAAI Annual Meeting
(January 2026) Announced 2026 pipeline outlook with three immunology programs (KIT, STAT6, MRGPRX2) and continued RSV Phase 3 enabling activities
(August 2025) Filed patent infringement action against Pfizer in European Union Unified Patent Court
(October 2025) Presented RSV clinical data showing efficacy improvements for both zelicapavir and EDP-323 at IDWeek 2025
Open the full interactive Enanta Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.